CaptBeer
Oct 3, 7:09 PM
$AMRN — EMT-2 could be a major inflection point
AMRN has fallen roughly 14% from its September high, yet the company’s reported cash + short-term investments were about
$315M as of June 30. At ~
$12.35, the market cap is only about
$261M.
If EMT-2 delivers spectacularly positive results, the story could shift from simply recovering the recent decline to a broader reassessment of icosapent ethyl’s value—potentially adding a significant oncology opportunity to the existing cardiovascular franchise.
This poster lays out the math behind
$15,
$20,
$25 and
$30 scenarios. These are illustrative valuation scenarios—not price targets or predictions.
0 replies
